ACS BIOMATER-SCI ENG:科学家研发出使HIV抑制剂更强大的新武器!

2017-06-23 佚名 Medicalxpress

UC默西德教授的研究小组已经弄清楚如何使一些最有效的艾滋病毒抑制剂更强大。李旺对这些发现感到非常Hang兴奋; 像美国国家卫生研究院(NIH)这样的资助机构却不是这样认为。

UC默西德教授的研究小组已经弄清楚如何使一些最有效的艾滋病毒抑制剂更强大。李旺对这些发现感到非常Hang兴奋; 像美国国家卫生研究院(NIH)这样的资助机构却不是这样认为。

李主任说:“我们的主要兴趣在于制造更好的艾滋病毒抗体。” “美国国家卫生研究院(NIH)对更强大的抑制剂不感兴趣,他们问我们“你们为什么不把这些研究集中在人的身上进行实践?”但是,将这些研究应用于人类身上目前还是有一些麻烦问题的。”

李旺的抑制剂是蛋白质,基于蛋白质的药物不能用于制作有效的药丸。问题本身不是药丸。问题是消化道。

消化道还存在酶,其中存在许多可以分解蛋白质的酶。这就是为什么,例如,没有胰岛素丸。胰岛素,也是一种蛋白质,仅在以绕过这些破坏蛋白酶的方式施用时才有效。这就是为什么通常注射胰岛素。吞下它,它不会起作用。李旺的艾滋病毒抑制剂与这个没有什么不同。

李旺需要一个替代交付系统。主题用途 - 即可以防止艾滋病毒性传播的可插入膜 - 似乎是最好的选择,但是第二个问题出现了。

除非仔细处理,否则基于蛋白质的药物往往会降解。制冷是关键; 任何温暖的条件药物都会失去效力。这是艾滋病毒药物的起始地,艾滋病毒药物必须在世界上获得气候控制储存有限的地区保持有效。

李旺被困住了。她开发出能够遏制艾滋病毒的强大药物,尽管在一个受控的实验室环境中。但她无法管理或稳定药物长期储存和使用。

光滑如丝的试剂

卡普兰集团在塔夫茨大学研究生物材料。在使用丝素蛋白的同时,他们发现了丝绸蛋白,他们发现了一些显着的蛋白质:丝心蛋白稳定蛋白质而不需要制冷。同样令人感兴趣的是丝心蛋白胶囊或膜可能提供用于局部递送HIV抑制剂的系统。

“大卫有一篇关于在丝中稳定麻疹,腮腺炎和风疹(MMR)疫苗的文章,”李旺说。 “我通过电子邮件告诉他们,我们正试图稳定我们的分子,但是我们会把药物用于局部使用,我告诉他,他的东西对我们来说是完美的。”

合作开始于2013年,证明立即卓有成效。到2014年,以前无动于衷的美国国家卫生研究院(NIH)授予李旺及其合作者四年,230万美元的资助,以支持这项工作。而现在这项工作正在实现。

该团队最近在“ACS生物材料”杂志“生物材料”中刊登了一篇文章 - “通过在丝素蛋白盘中包封来稳定和持续释放HIV抑制剂”,因为它们可以创建一种可以储存,稳定和局部施用基于蛋白质的HIV的基于丝绸的系统抑制剂。

通过市场上已有的许多有效选择,新的艾滋病毒抗体并不总是大的消息。但这不仅仅是一个新的抑制剂 - 它是一种新的输送系统。这可能会解决与艾滋病毒预防相关的一些持续的问题。

李旺和她的合作者表明,他们的丝绸稳定化抑制剂在高达122华氏度的温度下仍然有效能超过一年。虽然其他药物容易受到温度上升的影响,但李旺的抑制剂在几乎任何环境中仍然有效。对于像撒哈拉以南非洲地区,那些最容易受感染的地区,这些特点是非常关键的。

现有艾滋病毒药物的另一个问题涉及给药方案。大多数可用药物需要日常使用,但研究表明,许多高危人群不能遵守这一进度。李旺的丝蛋白系统提供了一个解决方案。它用可以插入的胶卷样物代替每日药丸,然后保持一个月的效力。

临床试验的希望

李旺警告说,她的团队的新系统尚未用于就诊。还有一些障碍。

丝蛋白系统需要在灵长目动物进行测试之后才能对人进行测试。加州大学戴维斯分校加州国家灵长类动物研究中心的Satya Dandekar教授正在与李旺合作,测试猕猴体内的系统。如果证明是安全和有效的,人类的试验将会遵循。

李旺希望她的制度将成为人类试验的“百分之一”,因为她相信它有潜力帮助处于世界资源贫乏地区的艾滋病毒风险最大的人群。

“我们正在精心设计可以做到经济实惠的蛋白质,”李旺说。 “这不会触及制药公司的底线,但可能有助于防止艾滋病毒在发展中国家的传播。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2081374, encodeId=8afe20813e4bc, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 09 14:09:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917535, encodeId=7d56191e53593, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 05 21:09:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851473, encodeId=119a18514e3d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 16 09:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216209, encodeId=a53d216209b5, content=HIV抑制剂的作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jun 28 07:26:33 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215303, encodeId=3d5e2153031b, content=有点困难,既然发现,就应完善所缺条件。加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicUw7yoAI4gptl6B3VGw6WZrBwAOwx2SfiafGGQAR5HcSI6IZVGvkthHYWlxfSGeSMz7KiablPqmJhCFP8wLMk7JFEkIFg7iaveU/0, createdBy=4bd02015384, createdName=医望无涯, createdTime=Sun Jun 25 17:00:42 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279172, encodeId=325012e917201, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300031, encodeId=5e9413000316c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214572, encodeId=8f7d2145e283, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Jun 24 01:57:47 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-07-09 spoonycyy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2081374, encodeId=8afe20813e4bc, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 09 14:09:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917535, encodeId=7d56191e53593, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 05 21:09:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851473, encodeId=119a18514e3d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 16 09:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216209, encodeId=a53d216209b5, content=HIV抑制剂的作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jun 28 07:26:33 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215303, encodeId=3d5e2153031b, content=有点困难,既然发现,就应完善所缺条件。加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicUw7yoAI4gptl6B3VGw6WZrBwAOwx2SfiafGGQAR5HcSI6IZVGvkthHYWlxfSGeSMz7KiablPqmJhCFP8wLMk7JFEkIFg7iaveU/0, createdBy=4bd02015384, createdName=医望无涯, createdTime=Sun Jun 25 17:00:42 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279172, encodeId=325012e917201, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300031, encodeId=5e9413000316c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214572, encodeId=8f7d2145e283, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Jun 24 01:57:47 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2018-06-05 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=2081374, encodeId=8afe20813e4bc, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 09 14:09:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917535, encodeId=7d56191e53593, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 05 21:09:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851473, encodeId=119a18514e3d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 16 09:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216209, encodeId=a53d216209b5, content=HIV抑制剂的作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jun 28 07:26:33 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215303, encodeId=3d5e2153031b, content=有点困难,既然发现,就应完善所缺条件。加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicUw7yoAI4gptl6B3VGw6WZrBwAOwx2SfiafGGQAR5HcSI6IZVGvkthHYWlxfSGeSMz7KiablPqmJhCFP8wLMk7JFEkIFg7iaveU/0, createdBy=4bd02015384, createdName=医望无涯, createdTime=Sun Jun 25 17:00:42 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279172, encodeId=325012e917201, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300031, encodeId=5e9413000316c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214572, encodeId=8f7d2145e283, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Jun 24 01:57:47 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2018-02-16 jklm09
  4. [GetPortalCommentsPageByObjectIdResponse(id=2081374, encodeId=8afe20813e4bc, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 09 14:09:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917535, encodeId=7d56191e53593, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 05 21:09:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851473, encodeId=119a18514e3d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 16 09:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216209, encodeId=a53d216209b5, content=HIV抑制剂的作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jun 28 07:26:33 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215303, encodeId=3d5e2153031b, content=有点困难,既然发现,就应完善所缺条件。加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicUw7yoAI4gptl6B3VGw6WZrBwAOwx2SfiafGGQAR5HcSI6IZVGvkthHYWlxfSGeSMz7KiablPqmJhCFP8wLMk7JFEkIFg7iaveU/0, createdBy=4bd02015384, createdName=医望无涯, createdTime=Sun Jun 25 17:00:42 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279172, encodeId=325012e917201, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300031, encodeId=5e9413000316c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214572, encodeId=8f7d2145e283, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Jun 24 01:57:47 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-06-28 jyzxjiangqin

    HIV抑制剂的作用。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2081374, encodeId=8afe20813e4bc, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 09 14:09:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917535, encodeId=7d56191e53593, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 05 21:09:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851473, encodeId=119a18514e3d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 16 09:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216209, encodeId=a53d216209b5, content=HIV抑制剂的作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jun 28 07:26:33 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215303, encodeId=3d5e2153031b, content=有点困难,既然发现,就应完善所缺条件。加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicUw7yoAI4gptl6B3VGw6WZrBwAOwx2SfiafGGQAR5HcSI6IZVGvkthHYWlxfSGeSMz7KiablPqmJhCFP8wLMk7JFEkIFg7iaveU/0, createdBy=4bd02015384, createdName=医望无涯, createdTime=Sun Jun 25 17:00:42 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279172, encodeId=325012e917201, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300031, encodeId=5e9413000316c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214572, encodeId=8f7d2145e283, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Jun 24 01:57:47 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-06-25 医望无涯

    有点困难,既然发现,就应完善所缺条件。加油

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2081374, encodeId=8afe20813e4bc, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 09 14:09:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917535, encodeId=7d56191e53593, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 05 21:09:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851473, encodeId=119a18514e3d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 16 09:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216209, encodeId=a53d216209b5, content=HIV抑制剂的作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jun 28 07:26:33 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215303, encodeId=3d5e2153031b, content=有点困难,既然发现,就应完善所缺条件。加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicUw7yoAI4gptl6B3VGw6WZrBwAOwx2SfiafGGQAR5HcSI6IZVGvkthHYWlxfSGeSMz7KiablPqmJhCFP8wLMk7JFEkIFg7iaveU/0, createdBy=4bd02015384, createdName=医望无涯, createdTime=Sun Jun 25 17:00:42 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279172, encodeId=325012e917201, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300031, encodeId=5e9413000316c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214572, encodeId=8f7d2145e283, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Jun 24 01:57:47 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-06-25 yaanren
  7. [GetPortalCommentsPageByObjectIdResponse(id=2081374, encodeId=8afe20813e4bc, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 09 14:09:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917535, encodeId=7d56191e53593, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 05 21:09:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851473, encodeId=119a18514e3d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 16 09:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216209, encodeId=a53d216209b5, content=HIV抑制剂的作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jun 28 07:26:33 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215303, encodeId=3d5e2153031b, content=有点困难,既然发现,就应完善所缺条件。加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicUw7yoAI4gptl6B3VGw6WZrBwAOwx2SfiafGGQAR5HcSI6IZVGvkthHYWlxfSGeSMz7KiablPqmJhCFP8wLMk7JFEkIFg7iaveU/0, createdBy=4bd02015384, createdName=医望无涯, createdTime=Sun Jun 25 17:00:42 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279172, encodeId=325012e917201, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300031, encodeId=5e9413000316c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214572, encodeId=8f7d2145e283, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Jun 24 01:57:47 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-06-25 lqvr
  8. [GetPortalCommentsPageByObjectIdResponse(id=2081374, encodeId=8afe20813e4bc, content=<a href='/topic/show?id=57406e8506' target=_blank style='color:#2F92EE;'>#Eng#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6785, encryptionId=57406e8506, topicName=Eng)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sun Jul 09 14:09:00 CST 2017, time=2017-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917535, encodeId=7d56191e53593, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Tue Jun 05 21:09:00 CST 2018, time=2018-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851473, encodeId=119a18514e3d0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri Feb 16 09:09:00 CST 2018, time=2018-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216209, encodeId=a53d216209b5, content=HIV抑制剂的作用。, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Jun 28 07:26:33 CST 2017, time=2017-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=215303, encodeId=3d5e2153031b, content=有点困难,既然发现,就应完善所缺条件。加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicUw7yoAI4gptl6B3VGw6WZrBwAOwx2SfiafGGQAR5HcSI6IZVGvkthHYWlxfSGeSMz7KiablPqmJhCFP8wLMk7JFEkIFg7iaveU/0, createdBy=4bd02015384, createdName=医望无涯, createdTime=Sun Jun 25 17:00:42 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279172, encodeId=325012e917201, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300031, encodeId=5e9413000316c, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Jun 25 06:09:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214572, encodeId=8f7d2145e283, content=学习过了,很好值得分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sat Jun 24 01:57:47 CST 2017, time=2017-06-24, status=1, ipAttribution=)]
    2017-06-24 明天会更好!

    学习过了,很好值得分享!

    0

相关资讯

Org Biomol Chem:科学家研发出一种能更有效抗击HIV的核苷修饰型新药!

随着艾滋病毒/艾滋病疫情进入其第四个十年,每年都会带来有前途的研究新消息,以减轻祸患。纽约市科学院的科学家也加入新研究,以快速的方法抑制引起艾滋病的病毒的新分子。

J Neurovirol:数学模型揭示了大脑中艾滋病毒感染的奥秘

由UAlberta研究团队开发的一种新的数学模型揭示了大脑中艾滋病毒感染的进展,临床医生和研究人员正在开发鼻喷雾剂来更有效地进行药物治疗。

Clin Infect Dis:HIV的母婴传播更容易发生在哪类人身上?

艾滋病病毒感染(HIV)阳性,在分娩时的尿液中存在巨细胞病毒或CMV的女性,比没有巨细胞病毒或CMV的HIV女性传播HIV给子女的可能性高5倍。加州大学洛杉矶分校牵头了这项研究。该研究发现,这些女性将巨细胞病毒传染给婴儿的可能性高30倍。

Immunity:科学家找到“运送”艾滋病疫苗的更佳方式,预防艾滋病指日可待!

艾滋病毒狡猾无比,它们成功的躲避着有效的疫苗,让科学家们束手无策。近日,来自斯克里普斯研究所的研究人员(TSRI)和拉霍亚免疫学研究所(LJI)的科学家们找到了新的突破口,他们最新的研究发表在最新一期的《免疫力》杂志中,此次研究表明优化疫苗交付方式和时机的重要性。

J Clin Invest:研究揭示HIV成功逃过抗病毒治疗,持久性存在的主要原因!

人体中大多数细胞的寿命有限,通常在数天或数周后死亡。然而,HIV-1感染的细胞数十年来一直存在于人体内。目前艾滋病毒治疗在抑制病毒方面非常有效,但不能完全清除疾病,如果治疗停止,可迅速复发。来自布里格姆妇女医院传染病科的Mathias Lichterfeld医学博士和Guinevere Lee博士领导的“临床调查杂志”发表的一项新研究揭示尽管进行抗病毒治疗但HIV-1感染持续存在的机制。

J Nat Prod :一种来源于植物的天然产物,抗HIV效果优于传统药物

植物中常常含有意外的惊喜。6月14日,《Journal of Natural Products 》期刊发表一篇题为“Potent Inhibitor of Drug-Resistant HIV-1 Strains Identified from the Medicinal Plant Justicia gendarussa”的文章,揭示了一种来源于东南亚植物的天然产物具有对抗艾滋病的潜能。